Thermo Fisher Scientific has enrolled the first patient in a prospective observational registry designed to generate real-world evidence on obesity treatments. The regirstry includes anti-obesity medications and GLP-1 receptor agonists. The PPD CorEvitas Obesity Registry will collect longitudinal data from both clinicians and patients. It will track how therapies are used in practice, how long…